Deals, Partnering

Affectis and Mitsubishi Tanabe Pharma in drug discovery collaboration

Posted on 06 April 2009

Tags: ,

Affectis will receive research fees from MTPC as well as development milestones. The collaboration applies Affectis’ extensive expertise in behavioural pharmacology to assist MTPC in discovering new anti-depressants in an ongoing drug discovery program. The discovery program is based on a novel depression target that Affectis helped validate in a previous collaboration between the two companies.

Print Friendly, PDF & Email

Leave a Reply